1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €36.68 (+214.85%). The median is €38.69 (+232.10%).
| Buy |
3 |
| Hold |
3 |
| Sell |
1 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 3.5K | 48.36% |
| Gross profit | 3.5K | 48.36% |
| Net profit | -39.21M | 8.29% |
| EBITDA | -37.27M | 3.21% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €302.71M |
Number of shares | 24.5M |
52-week high/low | €38.69 - €9.86 |
| Dividends | No |
Beta | -0.07 |
P/E ratio | -0.90 |
PEG ratio | 0.01 |
P/B ratio | 1.44 |
P/S ratio | 13,041.76 |
Company profile
| Name | LYELL IMMUNOPHARMA |
| CEO | Lynn Seely |
| Headquarters | South San Francisco,
ca USA |
| Sector | Materials |
| Industry | Chemicals |
| Employees | 161 |
Discover assets
Shareholders of LYELL IMMUNOPHARMA also invest in the following assets
